Overview

* Repare Therapeutics ( RPTX ) Q2 net loss narrows to $16.7 mln from $34.8 mln last year

* Co entered worldwide licensing agreement with Debiopharm for lunresertib

* Exploring strategic alternatives to maximize shareholder value

Outlook

* Company expects Q4 2025 data from LIONS and POLAR trials

* Repare exploring strategic alternatives to maximize shareholder value

* Company anticipates milestone payments from Debiopharm licensing deal

* Repare expects initial trial data in Q4 2025

Result Drivers

* OUT-LICENSING - Out-licensed early-stage discovery platforms to DCx Biotherapeutics, resulting in a $5.7 mln gain

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.39

Q2 Net -$16.74

Income mln

Q2 -$17.78

Income mln

From

Operatio

ns

Q2 $23.70

Operatin mln

g

Expenses

Q2 -$16.50

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Repare Therapeutics Inc ( RPTX ) is $5.00, about 69.6% above its August 7 closing price of $1.52

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)